This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1018 ISS

Dynavax Technologies Corporation

Drug Names(s): ISS-1018

Description: Dynavax Technologies is developing short, immunostimulatory DNA sequences (ISS). 1018 ISS is a CpG oligodeoxynucleotides (CpG-ODNs). CpG-ODNs affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).

1018 ISS News

Pink Sheet Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Pink Sheet Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study

Pink Sheet Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

Pink Sheet Novel Biologics In US Might Not Start Getting Suffixes Until August

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug